Sitagliptin/Metformin: A New Medical Treatment in Polycystic Ovary Syndrome.

Autor: Daneshjou D; Biology Department, Faculty of Science, Arak University, PO Box 3815688138, Arak, Iran., Soleimani Mehranjani M; Biology Department, Faculty of Science, Arak University, PO Box 3815688138, Arak, Iran. Electronic address: M-Soleimani@araku.ac.ir., Zadeh Modarres S; Men's Health and Reproductive Health Research Center, Shahid Beheshti, University of Medical Sciences, PO Box 1989930002, Tehran, Iran., Shariatzadeh MA; Biology Department, Faculty of Science, Arak University, PO Box 3815688138, Arak, Iran.
Jazyk: angličtina
Zdroj: Trends in endocrinology and metabolism: TEM [Trends Endocrinol Metab] 2020 Dec; Vol. 31 (12), pp. 890-892. Date of Electronic Publication: 2020 Oct 12.
DOI: 10.1016/j.tem.2020.09.002
Abstrakt: Metformin has long been used in the treatment of polycystic ovarian syndrome (PCOS). Recently, sitagliptin has been reported to improve ovarian cycles and ovulation in PCOS. We suggest that a combination of sitagliptin and metformin can be more effective than either treatment alone in improving different aspects of PCOS.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: